Intranasal midazolam was studied in two series of piglets: series 1, n= 20 (18±3 kg), a randomized double blind pharmacodynamic study to compare doses of 0.2 mg/kg and 0.4 mg/kg; series 2, n = 9 (42 ± 8 kg), a pharmacokinetic study with a 0.4 mg/kg dose administered either intravenously (i.v.) or intranasally (i.n.) in a cross-over protocol with a one-week wash-out period between each. In series 1, midazolam caused significant anxiolysis and sedation within 3 to 4 min, without a significant difference between 0.2 and 0.4 mg/kg doses for any of the studied parameters. In series 2, after intranasal midazolam administration of 0.4 mg/kg, plasma concentrations attained a maximum (Cmax) of 0.13 ± 0.04 mg/l at 5 min (median Tmax) and remained higher than 0.04 mg/l unti1.60 min. The bioavailability factor (F) in this study was F = 0.64 ± 0.17 by the intranasal route. The terminal half-life (Tl/2 AZ) = 145 ± 138 min was comparable with thei.v. administration half-life (158 ± 127 min). In conclusion, optimal intranasal midazolam dose in piglets was 0.2 mg/kg, which procures rapid and reliable sedation, adapted to laboratory piglets.
tional closed housing system at 22 ± 2°C, 75 ± 5% relative humidity with 24 h low intensity lighting. Two hundred animals were housed in groups of 25 per pen. The animals were then transferred to a specialized unit 300 m from the farm. Two series of animals were studied according to different acclimatization periods. In series I, the adaptation period was reduced to a 12 h fasting period. The 20 animals in this series remained four per pen, in a single room, before the experiment. In series 2, the period of adaptation to conditions in the boxes and cages lasted one week. Animals were kept in individual cages, with two cages per room. Temperature, humidity and lighting conditions remained constant. Animals were fed growing pigs diet (INRA 2213, Ets ARRIVE, 86250 St Fulgent, France) with unlimited tap water. All experiments were carried out during normal daylight hours.
Pharmacodynamic study
Series 1 enabled us to compare the clinical effects of intranasal administration of 0.2 vs 0.4 mg/kg midazolam (Hypnovel*, Roche, Neuilly-sur-Seine, France). A bolus of midazolam (5 mg/ml) was administered into a single nostril using a 2.5 ml syringe. Each animal's head was held upward for 3 s following the time of administration. Series 1 consisted of 20 piglets, 7.5 weeks of age, weighing 18±3 kg. It was divided into two groups of 10 in order to carry out a double blind study. Once randomized, the animals in group I received 0.2 mg/kg midazolam and in group II, 0.4 mg/kg. Animals were kept for 20 min in a cage and then transported to a second location 10 m away. An anaesthetic induction simulation using a mask was undertaken. Product administration ease was evaluated (0= difficult, 1= average, 2 = easy). Each animal's behaviour was noted at oneminute intervals with a three-point scale. In the cage, sedation characteristics were evaluated according to posture, palpebral droop, uninhibited behaviour and drowsiness; during transport, by the degree of agitation and the presence of grunting and after transport, by the heart rate (beats/min) and the acceptance of the anaesthetic mask.
Piglet posture was evaluated according to the following scale: 0 = standing; 1= lies down and gets back up, 2 = reclining. Palpebral droop was assessed as follows: 0 = eyes wide open, 1= moderate palpebral droop, 2 = clear cut palpebral droop. Uninhibited behaviour was scored as follows: 0 = retreat at the approach of a human hand, 1= moderate retreat, 2 = absence of retreat, animal allows its head to be touched. Drowsiness scores were as follows: 0 = animal steady on its feet, 1= starts staggering, 2 = clearly staggering. During transport, agitation and grunting were rated as follows: 0= none, 1= average, 2 = a lot. Finally, after transport, acceptance of anaesthetic mask was scored as: 0 = difficult, 1= average, 2= easy.
Intergroup and intragroup comparison of data (mean± SD) were performed using repeated analysis of variance (P<0.05) and Student's t-test (P<O.01l.
Pharmacokinetic studies
In the second series, nine piglets, aged 14± 3 weeks, weighing 42 ± 8 kg were studied. The drug was administered to each piglet as a standard injectable solution (Hypnovel*: 5 mg/ml) at a single dose of 0.4 mg/kg by i.v. or i.n. route in a cross-over protocol after a wash-out period of one week. The order in which the administration routes to each animal was randomized. Forty-eight hours prior topharmacokinetic studies, a percutaneous catheter was placed in the ear vein. A tunnelled catheter was placed in a jugular vein under general anaesthesia (halothane, nitrous oxide and oxygen). Before each procedure, the tunnelled catheter was connected to an extension, a three-way stopcock to ease blood sampling, a flow reducer (Uniflow Baxter, Bentley Laboratory Europe, 5400 Uden, Holland) and a perfusion of saline solution under pressure. Animals received 0.4 mg/kg midazolam either intranasally or via the ear vein. Central venous blood samples were drawn from the jugular and immediately injected into lithium heparin vacutainers. Samples were collected prior to and 5, 10, 15, 20, 30, 45, 60, 90, 120 and 240 min after midazolam administration. Plasma was separated by centrifugation at 4°C and stored at-80°C until analysis. Haematocrit and total serum protein levels were measured in blood drawn before midazolam administration. To determine both midazolam and 1 a.hydroxymidazolam plasma levels, we used a HPLC procedure described by Puglisi et al. (1985) . Neither metabolite was found in plasma specimens collected in piglets. HPLC with UV detection (218 nm) and an internal benzodiazepine standard (flurazepam) was used to analyse the samples. After liquid-liquid extraction from plasma followed by complete evaporation of the organic phase, the residue was dissolved in 100 l.tI of methanol then an aliquot of 20 III injected into the apparatus. The coefficient of variation was 8.6% (n = 10) with an accuracy of 97% at a concentration of 0.030 mg/L The detection limit of midazolam was 0.010 mg/l, with a signal-to-noise ratio of 4.
Pharmacokinetic calculations
Pharmacokinetic analysis was performed using the SIPHAR program (Gomeni 1983 ). An independent model (Giba1di 1982)was used to determine the kinetic parameters after i.v. and i.n. administrations. The apparent elimination half-life (TI/2 Azland the area under the concentration-time curve (AUC 0-+ t), (t = final sampling time) were calculated from the plasma concentration profiles of each piglet. For most of the animals, the plasma concentrations were measured only until 120 min because the limit of detection of midazolam was insufficient to determine the plasma concentration at 240 and 360 min. Individual bioavailability factors (F)were calculated as: AUC 0 -+ 120 min (i.n.l/AUC 0-+ 120 min (i.v.)for a same dose of 0.4 mg/kg. Cmax and Tmax were calculated for the i.n. route. Clearance ICl) and volume of distribution (Vd)were not calculated because we did not extrapolate the area under the curve (AUq between the last time of sampling and infinity.
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Results: pharmacodynamic study (series 1)
Intranasal injection was relatively easy in 16, average in 2 and difficult in 2 subjects. Sex ratio (15 females/5 males), mean weight 18 ±3 kg (range: 12-24 kg) and i.n. administration were comparable in both groups. Throughout the 20 min observation period of the piglets in their cages, the two groups were comparable in their posture, eyelid droopiness, uninhibited behaviour and stumbling. They were also comparable during and after transport with respect to agitation In =3/20), grunting (n=3/20) and pulse rate(154 ± 17beats/min) (range 114-189beats/ min). Combined analysis of the two groups revealed uninhibited behaviour and stumbling at the third and fourth minutes (P<O.Ol), followed by eyelid droop at the 11th min (P<O.Ol). Seven animals laid down at the 11th min (P<O.Ol), 11 out of 20 went down by the end of the observation period. The anaesthetic mask placement was relatively easy in 16, average in 2 and difficult in 2 animals.
Results: pharmacokinetic studies (series 2) Figure 1 shows the mean time course of plasma midazolam concentrations following i.v. and i.n. administration. Tables 1 and 2 summarize individual and mean kinetic data. Mean midazolam plasma concentrations after i.n. administration were lower than after i.v. administration during the first 90 min. These concentrations were very similar at 120 min. After a single dose of midazolam (0.4 mg/kg) by i.n. route, the bioavailability factor was F : 0.64 ± 0.17 (mean±SD), n=9. After i.n. measurement, the mean curve showed a rapid absorption, with average Cmax : 0.13 ± 0.04 mg/l observed 5 min (range 5-20 min) after administration. The terminal half-life (TI/2 ),z)obtained after i.n. administration 1145 ± 138 min) is comparable to that observed by i.v. administration (158± 127 min) (P=0.43, Wilcoxon signed rank testl. At minute 5 of observation, all animals had a plasma midazolam concentration piglets. in a cross-over protocol (n = 9 in each group of treatment). Dotted line: concentration required for activity above 0.040 mg/l which is considered to be the minimum therapeutic level for sedation in humans (Allonen et al. 1981) . Mean plasma concentrations after Ln. administration decreased to less than 0.040 mg/l after 60 min. In series 2, sedation occurred at the following times: drowsiness i.v. : 1 min, i.n. : 2.2 min, uninhibited behaviour i.v. : 1.2 min, i.n. : 2.6 min, palpebral droop i.v.: 1.2 min, Ln. : 3.6 min. In the i.v. group, a brief manual respiratory assistance was necessary for half of the animals. . The animals had a haematocrit of 28% ± 2% and a total plasma protein of 57 ± 5 gil.
Discussion
Midazolam is a fast acting water soluble benzodiazepine. Its main clinical properties are sedation and sleep inducement. As an anti-anxiety agent, it produces an interesting anterograde amnesia (Dundee et al. 1984 , Kanto et al. 1984 . Oral, intramuscular and intravenous administrations have been studied in the 1980s. In addition, this molecule is currently the object of investigations as to the administration modes which facilitate its use in animals and children. These modes are intranasal, rectal and mucous. Our study showed that at doses of 0.2 or 0.4 mg/kg, i.n. midazolam is an effective tranquillizer and sedative agent in piglets. Administration ease and rapid appearance of clinical effects make it a particularly useful product for the premedication of piglets in the laboratory. In piglets having received Ln. midazolam, a significant behavioural modification was apparent. Most of the piglets in series 1 were able to leave their cage easily and be calmly directed towards the anaesthesia site enabling a gentle anaesthetic induction simulation. None of the animals were excessively drowsy, and no apnoea was detected. These results are similar to those previously described in piglets at an i.n. dose This difference is not found in series 2, animals weighing 43 kg acclimatized for one week. Numerous studies have shown the effectiveness of Ln. midazolam as a premedication and sedation agent. In pre-school children, midazolam compared with an Ln. placebo was revealed as a tranquillizer and a sedative within 5 to 6 min with a maximum of effect between 9 and 12 min (Wilton et al. 1988 , Rose et ai. 1990 , Theroux et ai. 1993 , Davis et al. 1995 . It eases infant-parent separation, inhaled induction and wound sutures under local anaesthesia. It does not induce cardiovascular depression and does not delay anaesthetic recovery, nor hospital discharge, even after short intervention of about 10 min such as paracentesis, myringotomy or tube insertion. These studies are in accordance with our observation in piglets with one exception: a seemingly more rapid action in piglets (3 to 6 min vs 5 to 13.5 min in children). The difference is probably due to a more extensive nasal mucous surface in piglets. To our knowledge, in animals, i.n. midazolam use has been studied in rabbits /Robertson & Eberhart 1994) with a dose of 2 mg/kg, beagles (Lui et al. 1991 ) with a mean dose of 7.14 mg and piglets (Lacoste et al. 1997 ) with a dose of 0.2 mgjkg. In children, the results from four comparative studies at doses between 0.2 and 0.3 mg/kg have shown no significant difference in effectiveness. The recommended dose in children is 0.2 mg/kg (Wilton et al. 1988 , Fuks et al. 1994 , Otsuka et al. 1994 , Davis et al. 1995 . In the series 1 piglets, no significant clinical differences were shown between the 0.2 and 0.4 mgjkg doses throughout the entire study period «30 min). The optimal dose in piglets seems to be equivalent to doses in children, that is 0.2 mg/kg. In children, comparisons between other administration methods have shown the following: between intramuscular and sublingual (0.2 mgjkg)-no difference in effectiveness (de Santos et al. 1991) ; following oral administration (0.4-0.5 mg/kg)-identical or inferior effectiveness (Tolksdorf & Eick 1991 , Connors & Terndrup 1994 ; following rectal administration (0.35 mgjkg)-superior effectiveness (Houi et al. 1992) . A feeling of irritation is reported more frequently during nasal administration than during sublingual or rectal modes (Karl et al. 1993 , Griffith et al. 1998 . In piglets, sublingual, oral and rectal administration are difficult to carry out. One must take into account the notion of nasal irritation if this administration route is chosen and in the absence of another midazolam formula suitably designed for this route.
This study's pharmacokinetic data reinforces clinical observation reports. As in our previous study (1997) , where midazolam was dosed at 0.2 mg/kg, the speed of sedation appearance seems to correspond with an earlier Tmax in piglets than that reported in children. In piglets weighing 42 ± 8 kg and 25 ± 5 kg respectively, median Tmax = 5 min (range 5-20 min) with a 0.4 mg/kg dose and median Tmax=5 min (range 1-17.5 min) with a 0.2 mg/kg dose. In children weighing an average of 10 to 30 kg, the mean Tmax time shown in studies by Walbergh et a1. (1991) , Rey et a1. (1991) , Malinovsky et a1. (1993 and and Hisel et a1. (1995) was: Tmax = 11.7 min. Comparison of maximal concentrations after i.n. midazolam administration leads to the following results in piglets: Cmax = 0.130 ± 0.04 mg/l(range 0.080-0.210 mg/l) with a 0.4 mg/kg dose and emax = 0.167 ± 0.067 mg/l (range 0.088-0.284 mg/l) with a 0.2 mg/kg dose. In children, the analysis of reported Cmax by Rey et a1. (1991) , Malinovsky et a1. (1993 and 1995L and Hisel et a1.(1995 revealed similar results with an average Cmax=0.135 mg/l (range 0.069-0.352 mg/l) with a 0.2 mg/kg dose. It is noteworthy that re-absorption may have been modified in children because of slightly different methodologies. In two studies, midazolam was administered only after the induction of general anaesthesia and two others, the product was distributed between the two nostrils during 15 seconds. The terminal half-life is approximately 2.5 h in piglets, similar to that reported by Rey et a1. (1991j in children. Tl/2 elim=2.22± 1.19 h for intranasal administration. Other procedures, especially liquid chromatographymass spectrometry (LC-MS), allow the detection of plasma concentrations of midazolam under 0.010 mg/l (Eeckhoudt et a1. 1998 , Kanazawa et a1. 1998 . Such procedures could allow exact determination of the halflife elimination of midazolam. In our investigation, the 0.010 mg/l detection limit of the HPLC procedure restricted our calculation to the terminal half-life. Intranasal midazolam bioavailability is similar in piglets (64%) and in children (57%, Walbergh et a1. 1991 and 55%, Rey et a1. 1991) . However, it is greater than oral (F= 19%) or rectal (F= 18%) administration in children. This may be explained by a marked first passage effect after these administration routes.
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Conclusion
This study confirms that an Ln. midazolam approach is effective in inducing sedation and anxiolysis in young swine. Over a 30 min duration, a 0.4 mg/kg dose showed no additional clinical advantage with regard to a 0.2 mg/kg dose. Maximal plasma concentrations are attained by the 7th minute, but the 0.4 mg/kg dose remains above the 0.040 mg/l concentration, threshold for the appearance of clinical effects, until the 60th minute. Intranasal midazolam bioavailability at this dose is 64%, similar to that observed in children.
